Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy – results from two independent randomized trials
Tinne Laurberg(Aarhus University Hospital), Maggie C.U. Cheang(Institute of Cancer Research), Simen Myhre(Oslo University Hospital), Trine Tramm(Aarhus University Hospital), Thérese Sørlie(Norwegian Cancer Society), Silje Nord(Oslo University Hospital), Charles M. Perou(University of North Carolina at Chapel Hill), Torsten O. Nielsen(University of British Columbia), Karen A. Gelmon(University of British Columbia), Jens Overgaard(Aarhus University), Jan Alsner(Aarhus University Hospital), Aleix Prat(Hospital Clínic de Barcelona), Cheng Fan(University of North Carolina at Chapel Hill), David Voduc(BC Cancer Agency), Samuel Leung(BC Cancer Agency)
Cited by 31
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k